Should I Buy ACXP? ACXP 2026 Analysis

Should You Buy Acurx Pharmaceuticals Inc (ACXP) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Sell

Latest Price

2.590

1 Day change

-3.36%

52 Week Range

21.000

Analysis Updated At

2026/01/28

ACXP is not a good buy right now for a beginner long-term investor with $50k–$100k who wants action without waiting. The stock is in a bearish technical structure (SMA200 > SMA20 > SMA5), has no meaningful revenue, and losses/EPS deterioration continued in the latest quarter. With no supportive news flow and illiquid options, the risk/reward is unfavorable today—so the correct move is to avoid initiating and to sell/exit if already holding.

Technical Analysis

Price is ~2.68–2.70 pre-market, sitting near the pivot (2.695). Trend structure is bearish: SMA_200 > SMA_20 > SMA_5, indicating the longer-term downtrend is still intact. Momentum is mixed: MACD histogram is positive (0.0484) but contracting, suggesting a weakening bounce rather than a strong new uptrend. RSI(6) at 42.38 is neutral-to-soft, not signaling an oversold rebound. Key levels: support S1=2.55 (then S2=2.46); resistance R1=2.84 (then R2=2.93). From a setup perspective, upside requires reclaiming and holding above ~2.84; downside risk increases if 2.55 breaks.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Open interest: calls 977 vs puts 750 (OI put/call 0.77) implies slightly more call positioning than puts (mildly constructive). However, today’s options volume is 0 for both calls and puts, so there is effectively no real-time sentiment confirmation. IV metrics show low IV percentile (18.4) and low reported 30D IV (5.79) versus extremely high historical volatility (208.86), which, combined with zero volume, makes the options read less reliable/less actionable.

Technical Summary

Sell

Buy

Positive Catalysts

MACD remains above zero (still a bounce phase, even if weakening). Pattern-based projection provided suggests a positive 1-month outcome (+9.25% probability-weighted), meaning short-term rebounds are possible. Price is close to support (2.55), where buyers could defend.

Neutral/Negative Catalysts

Primary trend is bearish (SMA200 > SMA20 > SMA5), making rallies more likely to fail at resistance. No news catalysts in the past week to drive a re-rating. Options are illiquid (0 volume), limiting sentiment confirmation and making the stock more prone to gap moves. Fundamentals: no revenue and worsening YoY loss/EPS in the latest reported quarter increases dilution/financing risk typical for small pharma R&D names.

Financial Performance

Latest quarter: 2025/Q3. Revenue remained 0 (no operating revenue base). Net income fell to -1,992,790 (down 29.37% YoY), and EPS dropped to -1.23 (down 64.35% YoY). Overall: still pre-revenue with deteriorating profitability metrics, which is a weak backdrop for a long-term beginner-focused buy decision.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating/price target change data was provided, so a recent trend cannot be confirmed. Wall Street-style pros would be pipeline/clinical optionality and potential event-driven upside if trial/regulatory milestones succeed. Cons would be lack of revenue, ongoing losses, likely future capital raises, and high uncertainty—factors that generally make it unsuitable as a straightforward long-term beginner buy today. Intellectia Proprietary Trading Signals - [AI Stock Picker](module://ai_stock_pick): No signal on given stock today. - [SwingMax](module://swingmax): No signal on given stock recently. Influential/Political trading: No recent congress trading data available; hedge funds and insiders are neutral with no significant recent trends.

2 Analyst Rating

Wall Street analysts forecast ACXP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ACXP is 30.5 USD with a low forecast of 30 USD and a high forecast of 31 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

2 Buy

0 Hold

0 Sell

Moderate Buy

Current: 2.680

Low

Averages

30.5

High

Current: 2.680

Low

Averages

30.5

High

H.C. Wainwright

NULL -> Buy

upgrade

$8 -> $31

AI Analysis

2025-08-12

Reason

H.C. Wainwright

Price Target

$8 -> $31

AI Analysis

2025-08-12

upgrade

NULL -> Buy

Reason

H.C. Wainwright adjusted the firm's price target on Acurx to $31 from $8 and keeps a Buy rating on the shares following the recent 1-for-20 reverse stock split. The firm believes the company's lead asset ibezapolstat is making steady progress as it prepares to enter Phase 3 evaluation.

H.C. Wainwright

NULL

Buy

initiated

2025-05-15

Reason

H.C. Wainwright

Price Target

2025-05-15

initiated

NULL

Buy

Reason

H.C. Wainwright assumed coverage of Acurx with a Buy rating and $8 price target. Acurx is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria, the analyst tells investors in a research note. The firm believes the company is "flying under the radar with investors" into a "paradigm shifting moment in anti-infectives."

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for ACXP

Unlock Now

ACXP Should I Buy

ACXP Should I Buy

Should You Buy Acurx Pharmaceuticals Inc (ACXP) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch